For research use only. Not for therapeutic Use.
MAP4343 is the 3-methylether derivative of Pregnenolone. MAP4343 binds in vitro to microtubule-associated protein 2 (MAP2), stimulates the polymerization of tubulin, enhances the extension of neurites and protects neurons against neurotoxic agents[1][2].
MAP4343 (40 μM; 15 or 30 min) stimulates microtubule polymerization in vitro[1].
MAP4343 (30 μM; 2-8 d) stimulates nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells[1].
MAP4343 (20 μM; 1 h) protects against microtubule depolymerization induced by Nocodazole in PC12 cells[1]
MAP4343 (12 mg/kg; daily s.c. for 28 d) improves the recovery of locomotor function after spinal cord injury (SCI) in rats[2].
MAP4343 (4 mg/kg; daily s.c. for 6 d) increases MAP2 levels in spinal cord after SCI in rats[2].
MAP4343 (4 mg/kg; daily s.c. for 6 d) increases the size of lumbar spinal motoneurons’ dendrite arbours after SCI in rats[2].
| Catalog Number | I045663 |
| CAS Number | 511-26-2 |
| Synonyms | 1-[(3S,8S,9S,10R,13S,14S,17S)-3-methoxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone |
| Molecular Formula | C22H34O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C22H34O2/c1-14(23)18-7-8-19-17-6-5-15-13-16(24-4)9-11-21(15,2)20(17)10-12-22(18,19)3/h5,16-20H,6-13H2,1-4H3/t16-,17-,18+,19-,20-,21-,22+/m0/s1 |
| InChIKey | ZVGQOQHAMHMMNE-BIBIXIOVSA-N |
| SMILES | CC(=O)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC)C)C |
| Reference | [1]. Fontaine-Lenoir V, et, al. Microtubule-associated protein 2 (MAP2) is a neurosteroid receptor. Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4711-6. [2]. Duchossoy Y, et, al. Treatment of experimental spinal cord injury with 3β-methoxy-pregnenolone. Brain Res. 2011 Jul 27;1403:57-66. |
